Epstein-Barr virus infections: prospects for treatment

被引：74

作者：

Gershburg, E ^{[1
]}

Pagano, JS ^{[1
]}

机构：

[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 56卷 / 02期

关键词：

EBV; infectious mononucleosis; antiviral drugs;

D O I：

10.1093/jac/dki240

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Epstein-Barr virus (EBV) causes infectious mononucleosis and oral hairy leucoplakia, and is associated with a number of malignancies. There are, however, no regulatory agency-approved treatments for EBV-related diseases. Several antiviral drugs inhibit replication of EBV in cell culture including acyclic nucleoside and nucleotide analogues and pyrophosphate analogues, all of which inhibit the EBV DNA polymerase. Despite their potency in vitro, these drugs have limited use in vivo for treatment of acute primary EBV infection as well as EBV-associated malignancies for several reasons. Here we discuss novel anti-EBV compounds, including maribavir, potentially useful for the treatment of acute EBV infections. A number of experimental approaches for treatment of EBV-related malignancies that are not susceptible to conventional antiviral drug treatment are also discussed.

引用

页码：277 / 281

页数：5

共 70 条

[1] Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies [J].

Abdulkarim, B ;

Sabri, S ;

Zelenika, D ;

Deutsch, E ;

Frascogna, V ;

Klijanienko, J ;

Vainchenker, W ;

Joab, I ;

Bourhis, J .

ONCOGENE, 2003, 22 (15) :2260-2271

[2] Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action [J].

Biron, KK ;

Harvey, RJ ;

Chamberlain, SC ;

Good, SS ;

Smith, AA ;

Davis, MG ;

Talarico, CL ;

Miller, WH ;

Ferris, R ;

Dornsife, RE ;

Stanat, SC ;

Drach, JC ;

Townsend, LB ;

Koszalka, GW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2365-2372

[3] Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses [J].

Brideau, RJ ;

Knechtel, ML ;

Huang, A ;

Vaillancourt, VA ;

Vera, EE ;

Oien, NL ;

Hopkins, TA ;

Wieber, JL ;

Wilkinson, KF ;

Rush, BD ;

Schwende, FJ ;

Wathen, MW .

ANTIVIRAL RESEARCH, 2002, 54 (01) :19-28

[4] Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype [J].

Chodosh, J ;

Bolder, VP ;

Gan, YJ ;

Belgaumi, A ;

Sample, J ;

Sixbey, JW .

JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05) :1194-1201

[5] Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir [J].

Chou, SW ;

Marousek, GI ;

Senters, AE ;

Davis, MG ;

Biron, KK .

JOURNAL OF VIROLOGY, 2004, 78 (13) :7124-7130

[6] PHOSPHORYLATION OF ACYCLOVIR [9-(2-HYDROXYETHOXYMETHYL)GUANINE] IN EPSTEIN-BARR VIRUS-INFECTED LYMPHOBLASTOID CELL-LINES [J].

COLBY, BM ;

FURMAN, PA ;

SHAW, JE ;

ELION, GB ;

PAGANO, JS .

JOURNAL OF VIROLOGY, 1981, 38 (02) :606-611

[7] EFFECT OF ACYCLOVIR [9-(2-HYDROXYETHOXYMETHYL)GUANINE] ON EPSTEIN-BARR VIRUS-DNA REPLICATION [J].

COLBY, BM ;

SHAW, JE ;

ELION, GB ;

PAGANO, JS .

JOURNAL OF VIROLOGY, 1980, 34 (02) :560-568

[8] MECHANISM OF INHIBITION OF EPSTEIN-BARR VIRUS-REPLICATION BY PHOSPHONOFORMIC ACID [J].

DATTA, AK ;

HOOD, RE .

VIROLOGY, 1981, 114 (01) :52-59

[9] Antitumor potential of acyclic nucleoside phosphonates [J].

De Clercq, E ;

Andrei, G ;

Balzarini, J ;

Hatse, S ;

Liekens, S ;

Naesens, L ;

Neyts, J ;

Snoeck, R .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1999, 18 (4-5) :759-771

[10] Antivirals and antiviral strategies [J].

De Clercq, E .

NATURE REVIEWS MICROBIOLOGY, 2004, 2 (09) :704-720

← 1 2 3 4 5 6 7 →